What is the ROE (Return on Equity) of Vaccinex this year?
The ROE of Vaccinex this year is 8.76 undefined.
Vaccinex ROE 2024
Vaccinex ROE
8.76
Ticker
VCNX
ISIN
US9186401033
WKN
A2N30M
In 2024, Vaccinex's return on equity (ROE) was 8.76, a -329.65% increase from the -3.82 ROE in the previous year.
Vaccinex Aktienanalyse
What does Vaccinex do?
Vaccinex Inc is a biopharmaceutical company based in Rochester, New York, focusing on the development of novel therapies for a variety of diseases. The company was founded in 2001 by Maurice Zylofo and Dr. Steffen Nock, and has since built an impressive track record in drug development. Vaccinex's business model is based on the discovery and development of specific monoclonal antibodies for the treatment of diseases, particularly cancer. The company has developed a proprietary platform technology called ActivMAb®, which quickly and efficiently identifies potential targets and develops specific antibodies to block or modulate these targets. Vaccinex has several business divisions, including cancer therapy, immunology, cardiology, and neurology. Each of these divisions focuses on specific diseases and potential applications of Vaccinex's technology. The company also has partnerships with other industry leaders, such as Bristol-Myers Squibb and Catalent, to support the development and manufacturing of new drugs. The company has conducted several clinical trials to evaluate the efficacy and safety of its products. Vaccinex's most promising products are VX15/2503, a monoclonal antibody targeting cancer, and PEPCON, a potential vaccine for Alzheimer's disease. VX15/2503 is an antibody that targets the semaphorin 4-D receptor, a molecule that plays a key role in cancer development. The drug has shown in preclinical studies that it can inhibit tumor growth and has shown promise in clinical trials for the treatment of lung cancer and an aggressive brain tumor called glioblastoma. PEPCON is a novel vaccine targeting Alzheimer's disease. The vaccine aims to eliminate the beta-amyloid peptide, which is deposited in the brains of patients with Alzheimer's disease. The drug has shown in early clinical studies that it is able to reduce these brain deposits, which may lead to improved cognitive function. Overall, Vaccinex Inc has a promising future and is well-positioned to develop new and innovative therapies for the treatment of diseases. The company has an impressive track record in drug development and partnering with other industry leaders to support the manufacturing and commercialization of new drugs. With a strong pipeline of promising drug candidates, Vaccinex Inc will continue to play an important role in the development of new treatments. Vaccinex ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Vaccinex's Return on Equity (ROE)
Vaccinex's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Vaccinex's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Vaccinex's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Vaccinex’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Vaccinex stock
How has the Return on Equity (ROE) of Vaccinex developed compared to the previous year?
The ROE of Vaccinex has increased by -329.65% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Vaccinex?
A high ROE indicates that Vaccinex generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Vaccinex?
A low ROE can indicate that Vaccinex is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Vaccinex affect the company?
A change in ROE (Return on Equity) of Vaccinex can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Vaccinex?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Vaccinex?
Some factors that can influence Vaccinex's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Vaccinex pay?
Over the past 12 months, Vaccinex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaccinex is expected to pay a dividend of 0 USD.
What is the dividend yield of Vaccinex?
The current dividend yield of Vaccinex is .
When does Vaccinex pay dividends?
Vaccinex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Vaccinex?
Vaccinex paid dividends every year for the past 0 years.
What is the dividend of Vaccinex?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Vaccinex located?
Vaccinex is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vaccinex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vaccinex from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did Vaccinex pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of Vaccinex in the year 2023?
In the year 2023, Vaccinex distributed 0 USD as dividends.
In which currency does Vaccinex pay out the dividend?
The dividends of Vaccinex are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vaccinex
Our stock analysis for Vaccinex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaccinex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
